Hypha Labs

Hypha Labs Equity

The The Equity of Hypha Labs (FUNI) as of Oct 19, 2026 is -2.10 M USD. In the previous year, The Equity was -926,693.00 USD — a change of 126.95% (lower).

Equity

-2.10 MUSD

YoY

126.95%

Last updated:

In 2025, Hypha Labs's equity was -2.10 M USD, a 126.95% increase from the -926,693.00 USD equity in the previous year.

The Hypha Labs Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.01 M USD
Jan 1, 2019
425,866.00 USD
Jan 1, 2020
-1.09 M USD
Jan 1, 2021
-1.05 M USD
Jan 1, 2022
-2.41 M USD
Jan 1, 2023
-1.87 M USD
Jan 1, 2024
-926,693.00 USD
Jan 1, 2025
-2.10 M USD
The Hypha Labs Equity history
YEAREquityYoY
-2.10 MUSD+126.95%
-926,693.00USD-50.48%
-1.87 MUSD-22.32%
-2.41 MUSD+128.73%
-1.05 MUSD-3.29%
-1.09 MUSD-355.75%
425,866.00USD-58.03%
1.01 MUSD-27.90%
1.41 MUSD+13.95%
1.23 MUSD-47.65%
2.36 MUSD-59.54%
5.83 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hypha Labs Stock analysis

What does Hypha Labs do? Hypha Labs Inc, trading under the ticker symbol FUNI with ISIN US2538252022, is a United States-based entity operating within the Health Care sector. Headquartered in Las Vegas, Nevada, the company functions primarily as a service-oriented independent testing laboratory and data analytics firm. The organization maintains a relatively small workforce, employing 17 full-time staff members as of the latest available records. Hypha Labs Inc officially entered the public markets through an initial public offering on December 23, 2011. The company’s operational core is centered around its subsidiary, Digipath Labs, Inc., which serves as the primary vehicle for conducting cannabis-related testing services. This subsidiary utilizes FDA-compliant laboratory equipment and adheres to strict processing protocols to ensure the accuracy and safety of its analytical results. The firm positions itself as a critical third-party independent testing facility for a wide array of products, including medicinal and recreational cannabis, cannabis-infused products, hemp, and other botanical nutraceuticals. Its clientele is diverse, encompassing growers, dispensaries, caregivers, producers, patients, and ultimately, all end-users of cannabis and botanical products. The testing services provided by Digipath Labs are comprehensive, designed to screen products for various harmful contaminants that could pose risks to consumers. These contaminants include residual solvents, excessive moisture, and abnormal water activity levels. The laboratory also conducts thorough visual inspections to assess product quality and consistency. Furthermore, the facility tests for the presence of pesticides and heavy metals, which are common concerns in agricultural and botanical products. Biological toxins are another significant area of focus, with specific screening for aflatoxins and ochratoxins, which can be dangerous if ingested. Microbial contaminants are also rigorously tested for to ensure that the final products are safe for consumption. In addition to its testing capabilities, the company engages in providing education, training, and news coverage related to the cannabis industry, thereby supporting the broader ecosystem of stakeholders involved in botanical health and wellness. The company’s website, https://www.digipath.com/, serves as a hub for information regarding its services and industry insights. By maintaining independence and compliance with federal standards, Hypha Labs Inc aims to provide reliable data and safety assurances to a market that is increasingly regulated and consumer-focused. Hypha Labs is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Hypha Labs's Equity

Hypha Labs's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Hypha Labs's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Hypha Labs's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Hypha Labs's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Hypha Labs’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Hypha Labs stock

The Equity of Hypha Labs is -2.10 M USD in 2025.

The Equity of Hypha Labs changed from -926,693.00 USD to -2.10 M USD, representing a 126.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Hypha Labs since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Hypha Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hypha Labs

All Key Metrics — Hypha Labs